1-3 of 3
Heidrun Gevensleben
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Triplet Therapy with Palbociclib, Taselisib, and Fulvestrant in PIK3CA-Mutant Breast Cancer and Doublet Palbociclib and Taselisib in Pathway-Mutant Solid Cancers

Javier Pascual, Joline S.J. Lim, Iain R. Macpherson, Anne C. Armstrong, Alistair Ring, Alicia F.C. Okines, Rosalind J. Cutts, Maria Teresa Herrera-Abreu, Isaac Garcia-Murillas, Alex Pearson, Sarah Hrebien, Heidrun Gevensleben, Paula Z. Proszek, Michael Hubank, Margaret Hills, Jenny King, Mona Parmar, Toby Prout, Laura Finneran, Jason Malia, Karen E. Swales, Ruth Ruddle, Florence I. Raynaud, Alison Turner, Emma Hall, Timothy A. Yap, Juanita S. Lopez, Nicholas C. Turner
Journal: Cancer Discovery
Series: Author Choice
Cancer Discov (2021) 11 (1): 92–107.
https://doi.org/10.1158/2159-8290.CD-20-0553
Published: 06 January 2021
View article titled, Triplet Therapy with Palbociclib, Taselisib, and Fulvestrant in <em>PIK3CA</em>-Mutant Breast Cancer and Doublet Palbociclib and Taselisib in Pathway-Mutant Solid Cancers
Open the PDF for Triplet Therapy with Palbociclib, Taselisib, and Fulvestrant in <em>PIK3CA</em>-Mutant Breast Cancer and Doublet Palbociclib and Taselisib in Pathway-Mutant Solid Cancers in another window
Includes: Supplementary data
Journal Articles

Phase I Trial of the PARP Inhibitor Olaparib and AKT Inhibitor Capivasertib in Patients with BRCA1/2- and Non–BRCA1/2-Mutant Cancers

Timothy A. Yap, Rebecca Kristeleit, Vasiliki Michalarea, Stephen J. Pettitt, Joline S.J. Lim, Suzanne Carreira, Desamparados Roda, Rowan Miller, Ruth Riisnaes, Susana Miranda, Ines Figueiredo, Daniel Nava Rodrigues, Sarah Ward, Ruth Matthews, Mona Parmar, Alison Turner, Nina Tunariu, Neha Chopra, Heidrun Gevensleben, Nicholas C. Turner, Ruth Ruddle, Florence I. Raynaud, Shaun Decordova, Karen E. Swales, Laura Finneran, Emma Hall, Paul Rugman, Justin P.O. Lindemann, Andrew Foxley, Christopher J. Lord, Udai Banerji, Ruth Plummer, Bristi Basu, Juanita S. Lopez, Yvette Drew, Johann S. de Bono
Journal: Cancer Discovery
Series: Author Choice
Cancer Discov (2020) 10 (10): 1528–1543.
https://doi.org/10.1158/2159-8290.CD-20-0163
Published: 01 October 2020
View article titled, Phase I Trial of the PARP Inhibitor Olaparib and AKT Inhibitor Capivasertib in Patients with <em>BRCA1/2</em>- and Non–<em>BRCA1/2</em>-Mutant Cancers
Open the PDF for Phase I Trial of the PARP Inhibitor Olaparib and AKT Inhibitor Capivasertib in Patients with <em>BRCA1/2</em>- and Non–<em>BRCA1/2</em>-Mutant Cancers in another window
Includes: Supplementary data
Journal Articles

Forced Mitotic Entry of S-Phase Cells as a Therapeutic Strategy Induced by Inhibition of WEE1

Marieke Aarts, Rachel Sharpe, Isaac Garcia-Murillas, Heidrun Gevensleben, Melissa S. Hurd, Stuart D. Shumway, Carlo Toniatti, Alan Ashworth, Nicholas C. Turner
Journal: Cancer Discovery
Cancer Discov (2012) 2 (6): 524–539.
https://doi.org/10.1158/2159-8290.CD-11-0320
Published: 07 June 2012
View article titled, Forced Mitotic Entry of S-Phase Cells as a Therapeutic Strategy Induced by Inhibition of WEE1
Open the PDF for Forced Mitotic Entry of S-Phase Cells as a Therapeutic Strategy Induced by Inhibition of WEE1 in another window
Includes: Supplementary data